Praxis precision medicines receives fda breakthrough therapy designation for relutrigine for the treatment of seizures associated with scn2a and scn8a developmental and epileptic encephalopathies

The breakthrough therapy designation (btd) was granted based on the highly compelling results from the phase 2 embold trial in scn2a and scn8a developmental and epileptic encephalopathies (dees)
PRAX Ratings Summary
PRAX Quant Ranking